The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain ...

For millions of Americans, paying for the treatment needed to manage their diseases can become its own lifelong problem.

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

The National Institutes of Health has awarded a five-year, $2.79 million grant to Shuying Yang and Michael Mitchell for their ...

this effect diminished once participants stopped the medication. In the ARIAA and APIPPRA trials using abatacept, “it wasn’t like we hit a reset button and [patients] just permanently now did not get ...

New research shows that weight loss drugs semaglutide, known as Ozempic and Wegovy, not only aid in weight loss but also ...

New research shows that blood-based immunophenotyping can enhance rheumatoid arthritis treatment by identifying immune ...

In a groundbreaking new study, Ozempic was found to be so effective at treating arthritis that people no longer needed ...

A new study reported in the New England Journal of Medicine found that GLP-1 drugs such as Ozempic and Wegovy which have ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Subcutaneous semaglutide is currently marketed under the brand name Wegovy for chronic weight management and to reduce the risk of major adverse cardiovascular events in adults with established ...